{
}
UBS has maintained a 'Neutral' rating for Novo Nordisk with a target price of 1100 Danish crowns. Despite the company's forecast of high growth for 2025, UBS's estimates are lower than market expectations, leading to a notable fluctuation in share prices following the announcement.
Novo Nordisk reported a strong third quarter, with profits reaching 33.8 billion Danish kroner ($4.88 billion), slightly above forecasts. Sales of its obesity drug Wegovy surged to 17.3 billion kroner ($2.5 billion), contributing to a 44% increase in the obesity care business, leading to a 7% rise in shares.
UBS has lowered its target price for Demant to DKK 300 from DKK 320 while maintaining a Buy rating. Demant A/S, the world's second-largest audio product manufacturer, generates net sales primarily from customized hearing aids (44.7%) and hearing aids (40.5%), with significant sales in the U.S. (34.1%) and Europe (29.7%).
UBS has reduced its target price for Demant to DKK 300 while reaffirming its takeover offer. Demant A/S, a leading hearing aid manufacturer, generates sales primarily from custom hearing aids (44.7%) and hearing care products (40.5%), with significant markets in the U.S. (34.1%) and Europe (29.7%).
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted that the market is likely to respond positively to the figures, particularly due to a significant cap on the sales target.
Novo Nordisk's Wegovy sales surged 79% to 17.3 billion Danish kroner ($2.5 billion) last quarter, driven by its expansion into new markets. In the US, sales increased by about 50% despite falling prices, as more insurers began covering the drug, providing a boost amid rival Eli Lilly's disappointing obesity sales.
Novo Nordisk is poised to report its third-quarter earnings, with analysts optimistic about the stock, reflected in six "buy" and five "hold" ratings. The average price target is set at 963.36 Danish krone, approximately 28% above recent levels, driven by anticipated sales growth of its weight-loss drugs, Ozempic and Wegovy. However, increased competition in the weight-loss market could pose challenges, despite analysts noting the company's strong production advantages.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a moderate increase in prescription figures for the weight loss drug Wegovy in the USA, based on the latest data.
UBS has raised its target price for Danske Bank to DKK 245, maintaining a Buy rating. As Denmark's leading bank, Danske Bank operates in four key areas: retail banking, market and investment banking, insurance through Danica Pension, and other asset management services. By the end of 2023, the Group managed DKK 1,222.2 billion in current deposits and DKK 928.2 billion in current loans.
UBS has reduced its price target for Jyske Bank to DKK 510 from DKK 585 while maintaining a neutral stance. Jyske Bank A/S, Denmark's third-largest independent bank, derives 72.7% of its income from banking activities, 21.6% from real estate and mortgage lending, and 5.7% from leasing. As of the end of 2023, the bank managed DKK 218.3 billion in current deposits and DKK 557.3 billion in current loans, primarily serving the Danish market.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
Danish Krone
UBS AG
Novo Nordisk A/S
DNK
Hubert Dichtl
Warren Buffet
Thomas Müller
Jo Walton
Show more
21:07 06.11.2024
Novo Nordisk reports strong earnings as Wegovy sales surge in Q3
10:03 06.11.2024
ubs lowers target price for demant while maintaining buy rating
10:00 06.11.2024
ubs lowers demant target price and maintains takeover offer
10:00 06.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
09:40 06.11.2024
wegovy sales surge as international availability expands and us insurers cover costs
07:42 06.11.2024
analysts optimistic on novo nordisk ahead of third quarter earnings report
Danish Krone
United States Dollar
AstraZeneca PLC
Novo Nordisk A/S
Eli Lilly and Company
Viking Therapeutics, Inc.
DNK
Show more
22:16 04.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
13:26 04.11.2024
ubs raises target price for danske bank to dkk 245
09:59 01.11.2024
ubs lowers jyske bank price target to dkk 510 remains neutral
10:00 31.10.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: